Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

A “fluorescence switch” technique increases the sensitivity of proteomic detection and identification of S‐nitrosylated proteins

  • Tello, Daniel
  • Tarín, Carlos
  • Ahicart, Patricia
  • Bretón‐Romero, Rosa
  • Lamas, Santiago
  • Martínez Ruiz, Antonio
Protein S-nitrosylation is a reversible post-translational modification of protein cysteines that is increasingly being considered as a signal transduction mechanism. The ‘‘biotin switch’’ technique marked the beginning of the study of the S-nitrosoproteome, based on the specific replacement of the labile S-nitrosylation by a more stable biotinylation that allowed further detection and purification. However, its application for proteomic studies is limited by its relatively low sensitivity. Thus, typical proteomic experiments require high quantities of protein extracts, which precludes the use of this method in a number of biological settings. We have developed a ‘‘fluorescence switch’’ technique that, when coupled to 2-DE proteomic methodologies, allows the detection and identification of S-nitrosylated proteins by using limited amounts of starting material, thus significantly improving the sensitivity. We have applied this methodology to detect proteins that become S-nitrosylated in endothelial cells when exposed to S-nitroso-L-cysteine, a physiological S-nitrosothiol, identifying already known S-nitrosylation targets, as well as proteins that are novel targets. This ‘‘fluorescence switch’’ approach also allowed us to identify several proteins that are denitrosylated by thioredoxin in cytokine-activated RAW264.7 (murine macrophage) cells. We believe that this method represents an improvement in order to approach the identification of S-nitrosylated proteins in physiological conditions.
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Cohort profile: The Girona heart registry

  • Degano, Irene R.
  • Herrera-Marín, Nuria
  • Subirana, Isaac
  • Camps-Vilaró, Anna
  • Hernáez, Álvaro
  • Sala, Joan
  • Masià, Rafael
  • Ramos, Rafel
  • Elosua, Roberto
  • Marrugat, Jaume
The Girona Heart Registry (REGICOR) is a population-based study designed to analyse the magnitude of and factors related to cardiovascular (CV) diseases in Southern Europe. The REGICOR cohort integrates the participants of four population-based surveys conducted in 1995, 2000, 2005, and 2018 in the Girona province (North-Eastern Spain), with a current reference population of approximately 790 000 inhabitants. The REGICOR cohort includes 11 631 individuals (1748 in 1995, 3030 in 2000, 6308 in 2005, and 545 in 2018). At inclusion, 52% of the study population were females; their mean ages were 51, 50, 57, and 45, respectively. Two re-examinations were conducted for the participants recruited in 1995, 2000, and 2005. Follow-up data on CV events and cause-specific mortality are available for 11 518 participants since baseline, with a median follow-up time of 18.6 years. Follow-up data on non-CV events have been available since 2008. During inclusion and re-examinations, we obtained blood samples and information on CV and other risk factors using validated questionnaires, standardized tests, and imaging assessments. Genotyping was performed on the whole cohort. Circulating biomarkers, DNA methylation, microRNAs, and proteomics have been measured in a cohort subset., info:eu-repo/semantics/publishedVersion
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility

  • Picelli, S.
  • Lorenzo Bermejo, J.
  • Chang Claude, J.
  • Hoffmeister, M.
  • Fernández Rozadilla, C.
  • Carracedo, A.
  • Castells, A.
  • Castellví Bel, S.
  • Juan, D.M.
  • Raquel, M.
  • Marisa, M.
  • Francisco, C.
  • Jose, D.
  • Carolina, I.
  • Guadalupe, L.
  • Alberto, I.
  • Antoni, C.
  • Virgínia, P.
  • Sergi, C.B.
  • Balaguer, F.
  • Victoria, G.
  • Teresa, O.
  • María Dolores, G.
  • Maria, P.
  • Anna, S.
  • Leticia, M.
  • Miriam, C.
  • Josep, M.P.
  • Lanas, A.
  • Alcedo, J.
  • Ortego, F.J.
  • Joaquin, C.
  • Ma, S.D.
  • Mercedes, S.
  • Eloy, S.
  • Mariano, V.
  • Montserrat, A.
  • Anna, A.
  • Xavier, B.
  • Mar, I.
  • Agustín, S.
  • Felipe, B.
  • Gemma, N.
  • Beatriz, B.
  • De Josep, M.
  • Cristina, Á.
  • Marc, P.
  • Luis, B.
  • Ángel, C.
  • Inés, G.
  • Mikel, L.
  • Carlos, P.
  • María, d.M.R.
  • Elisabeth, H.
  • Jose, M.E.N.
  • Jose, L.E.
  • Artemio, P.
  • Rodrigo, J.
  • Cristina, A.
  • Laura, S.
  • Nuria, A.
  • Estefanía, R.
  • Lucía, P.C.
  • Joaquim, R.
  • Ángel, S.
  • Anna, G.
  • Joan, S.
  • Eduard, B.A.
  • Josefina, A.
  • Ramon, B.
  • Ana, M.G.
  • Fernando, C.
  • Antonio, B.
  • Eduardo, S.
  • Fernando, G.
  • Jaime, S.
  • Akiko, O.
  • Mercedes, L.
  • Enrique, M.
  • Jaime, C.
  • Pilar, C.
  • Miguel, M.
  • José, A.G.
  • Francisco, Q.
  • Elisa, O.
  • Juan, C.
  • Jaime, S.
  • Antoni, T.
  • Eugenia, S.
  • de Ma, L.C.
  • Antoni, T.
  • Juan, C.
  • Vicent, H.
  • Xavier, L.
  • Rosa, M.X.
  • Marta, P.
  • Mercè, R.
  • Anna, R.
  • Elisenda, P.
  • José, M.H.
  • Miquel, A.G.
  • Fernando, F.B.
  • Josep, M.V.
  • Antonio, S.
  • Jorge, E.
  • Montserrat, F.
  • Maria, E.
  • Josep, M.R.
  • Carmen, P.
  • Juan, B.
  • Joan, V.
  • Enrique, Q.
  • David, N.
  • Adolfo, P.
  • Antonio, M.
  • Lidia, A.
  • Vicente, P.
  • Virginia, P.
  • Teresa, S.
  • Dolors, G.
  • Eva, R.
  • Teresa, R.
  • Maria, P.
  • Ma, M.C.
  • Marta, M.
  • Lourdes, P.
  • Daniel, M.
  • Ángel, C.
  • Clara, R.P.
  • Ceres, F.R.
  • Ma, M.C.
  • Sabino, R.
  • Luis, R.
  • Javier, F.
  • Jose, L.C.
  • Luis, C.
  • Susana, O.
  • Federico, B.
  • Elena, P.
  • José, M.B.
  • Gloria, C.
  • Juan, J.S.
  • Antonio, N.
  • Naccarati, A.
  • Pardini, B.
  • Vodickova, L.
  • Müller, H.
  • Talseth Palmer, B.A.
  • Stibbard, G.
  • Peterlongo, P.
  • Nici, C.
  • Veneroni, S.
  • Li, L.
  • Casey, G.
  • Tenesa, A.
  • Farrington, S.M.
  • Tomlinson, I.
  • Moreno, V.
  • van Wezel, T.
  • Wijnen, J.
  • Dunlop, M.
  • Radice, P.
  • Scott, R.J.
  • Vodicka, P.
  • Ruiz Ponte, C.
  • Brenner, H.
  • Buch, S.
  • Völzke, H.
  • Hampe, J.
  • Schafmayer, C.
  • Lindblom, A.
In the last four years, Genome-Wide Association Studies (GWAS) have identified sixteen low-penetrance polymorphisms on fourteen different loci associated with colorectal cancer (CRC). Due to the low risks conferred by known common variants, most of the 35% broad-sense heritability estimated by twin studies remains unexplained. Recently our group performed a case-control study for eight Single Nucleotide Polymorphisms (SNPs) in 4 CRC genes. The present investigation is a follow-up of that study. We have genotyped six SNPs that showed a positive association and carried out a meta-analysis based on eight additional studies comprising in total more than 8000 cases and 6000 controls. The estimated recessive odds ratio for one of the SNPs, rs3219489 (MUTYH Q338H), decreased from 1.52 in the original Swedish study, to 1.18 in the Swedish replication, and to 1.08 in the initial meta-analysis. Since the corresponding summary probability value was 0.06, we decided to retrieve additional information for this polymorphism. The incorporation of six further studies resulted in around 13000 cases and 13000 controls. The newly updated OR was 1.03. The results from the present large, multicenter study illustrate the possibility of decreasing effect sizes with increasing samples sizes. Phenotypic heterogeneity, differential environmental exposures, and population specific linkage disequilibrium patterns may explain the observed difference of genetic effects between Sweden and the other investigated cohorts.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Beverage consumption patterns and their association with metabolic health in adults from families at high risk for type 2 diabetes in Europe—The Feel4Diabetes study

  • Kantaras, Paris
  • Mourouti, Niki
  • Mouratidou, Theodora
  • Chatzaki, Ekaterini
  • Karaglani, Makrina
  • Iotova, Violeta
  • Usheva, Natalya
  • Rurik, Imre
  • Torzsa, Péter
  • Moreno, Luis A.
  • Liatis, Stavros
  • Makrilakis, Konstantinos
  • Manios, Yannis
  • Civeira, Fernando
  • Bueno, Gloria
  • De Miguel-Etayo, Pilar
  • González-Gil, Esther M.
  • Miguel-Berges, María L.
  • Giménez-Legarre, Natalia
  • Flores-Barrantes, Paloma
  • Ayala-Marín, Alelí M.
  • Seral-Cortés, Miguel
  • Baila-Rueda, Lucía
  • Cenarro, Ana
  • Jarauta, Estíbaliz
  • Mateo-Gallego, Rocío
In total, 3274 adults (65.2% females) from six European countries were included in this cross-sectional analysis using data from the baseline assessment of the Feel4Diabetes study. Anthropometric, sociodemographic, dietary and behavioral data were assessed, and the existence of metabolic syndrome (MetS) was recorded. Beverage consumption patterns (BCPs) were derived via principal component analysis. Three BCPs were derived explaining 39.5% of the total variation. BCP1 was labeled as “Alcoholic beverage pattern”, which loaded heavily on high consumption of beer/cider, wine and other spirits; BCP2 was labeled as “High in sugars beverage pattern” that was mainly characterized by high consumption of soft drinks with sugar, juice containing sugar and low consumption of water; and BCP3 was labeled as “Healthy beverage pattern” that was mainly characterized by high consumption of water, tea, fruit juice freshly squeezed or prepacked without sugar and low consumption of soft drinks without sugar. After adjusting for various confounders, BCP2 was positively associated with elevated triglycerides (p = 0.001), elevated blood pressure (p = 0.001) elevated fasting glucose (p = 0.008) and the existence of MetS (p = 0.006), while BCP1 was inversely associated with reduced HDL-C (p = 0.005) and BCP3 was inversely associated with elevated blood pressure (p = 0.047). The establishment of policy actions as well as public health nutritional education can contribute to the promotion of a healthy beverage consumption.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cohort profile: The Girona heart registry

  • Degano, Irene R.
  • Herrera-Marín, Nuria
  • Subirana, Isaac
  • Camps-Vilaró, Anna
  • Hernáez, Álvaro
  • Sala, Joan
  • Masià, Rafael
  • Ramos, Rafel
  • Elosua, Roberto
  • Marrugat, Jaume
The Girona Heart Registry (REGICOR) is a population-based study designed to analyse the magnitude of and factors related to cardiovascular (CV) diseases in Southern Europe. The REGICOR cohort integrates the participants of four population-based surveys conducted in 1995, 2000, 2005, and 2018 in the Girona province (North-Eastern Spain), with a current reference population of approximately 790 000 inhabitants. The REGICOR cohort includes 11 631 individuals (1748 in 1995, 3030 in 2000, 6308 in 2005, and 545 in 2018). At inclusion, 52% of the study population were females; their mean ages were 51, 50, 57, and 45, respectively. Two re-examinations were conducted for the participants recruited in 1995, 2000, and 2005. Follow-up data on CV events and cause-specific mortality are available for 11 518 participants since baseline, with a median follow-up time of 18.6 years. Follow-up data on non-CV events have been available since 2008. During inclusion and re-examinations, we obtained blood samples and information on CV and other risk factors using validated questionnaires, standardized tests, and imaging assessments. Genotyping was performed on the whole cohort. Circulating biomarkers, DNA methylation, microRNAs, and proteomics have been measured in a cohort subset., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease

  • Lacoma, Alicia|||0000-0002-2049-3872
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Andreo García, Felipe|||0000-0003-4842-9597
  • Lores, Luis
  • Ruiz Manzano, Juan|||0000-0001-7213-7346
  • Ausina, Vicente|||0000-0002-1798-9869
  • Domínguez, José|||0000-0001-7888-0309
The identification of biological markers in order to assess different aspects of COPD is an area of growing interest. The objective of this study was to investigate whether levels of procalcitonin (PCT), C-reactive protein (CRP), and neopterin in COPD patients could be useful in identifying the etiological origin of the exacerbation and assessing its prognosis. We included 318 consecutive COPD patients: 46 in a stable phase, 217 undergoing an exacerbation, and 55 with pneumonia. A serum sample was collected from each patient at the time of being included in the study. A second sample was also collected 1 month later from 23 patients in the exacerbation group. We compared the characteristics, biomarker levels, microbiological findings, and prognosis in each patient group. PCT and CRP were measured using an immunofluorescence assay. Neopterin levels were measured using a competitive immunoassay. PCT and CRP showed significant differences among the three patient groups, being higher in patients with pneumonia, followed by patients with exacerbation (P < 0.0001). For the 23 patients with paired samples, PCT and CRP levels decreased 1 month after the exacerbation episode, while neopterin increased. Neopterin showed significantly lower levels in exacerbations with isolation of pathogenic bacteria, but no differences were found for PCT and CRP. No significant differences were found when comparing biomarker levels according to the Gram result: PCT (P = 0.191), CRP (P = 0.080), and neopterin (P = 0.109). However, median values of PCT and CRP were high for Streptococcus pneumoniae, Staphylococcus aureus, and enterobacteria. All biomarkers were higher in patients who died within 1 month after the sample collection than in patients who died later on. According to our results, biomarker levels vary depending on the clinical status. However, the identification of the etiology of infectious exacerbation by means of circulating biomarkers is encouraging, but its main disadvantage is the absence of a microbiological gold standard, to definitively demonstrate their value. High biomarker levels during an exacerbation episode correlate with the short-term prognosis, and therefore their measurement can be useful for COPD management.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TSPAN1, a Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance

  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Carballo, Laia
  • Castellvi, Josep|||0000-0001-5745-9996
  • Temprana-Salvador, Jordi|||0000-0001-9516-1680
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Benavente, Sergi|||0000-0002-2700-3522
  • García-Pedrero, Juana María|||0000-0002-5891-9488
  • Allonca, Eva|||0000-0002-2532-5421
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial-mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Therapy-Induced Modulation of the Tumor Microenvironment, New Opportunities for Cancer Therapies

  • Benavente, Sergi|||0000-0002-2700-3522
  • Sánchez García, Almudena
  • Naches Solsona, Silvia
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low curability, but their effects are limited, and increasing evidence has implicated tumoral and non-tumoral components of the tumor microenvironment as critical mediators of cancer progression. At the same time, the clinical successes achieved with minimally invasive and optically-guided surgery and image-guided and ablative radiation strategies have been successfully implemented in clinical care. More effective, localized and safer treatments have fueled strong research interest in radioimmunotherapy, which has shown the potential immunomodulatory effects of ionizing radiation. However, increasingly more observations suggest that immunosuppressive changes, metabolic remodeling, and angiogenic responses in the local tumor microenvironment play a central role in tumor recurrence. In this review, we address challenges to identify responders vs. non-responders to the immune checkpoint blockade, discuss recent developments in combinations of immunotherapy and radiotherapy for clinical evaluation, and consider the clinical impact of immunosuppressive changes in the tumor microenvironment in the context of surgery and radiation. Since the therapy-induced modulation of the tumor microenvironment presents a multiplicity of forms, we propose that overcoming microenvironment related resistance can become clinically relevant and represents a novel strategy to optimize treatment immunogenicity and improve patient outcome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting Sphingolipids for Cancer Therapy

  • Companioni, Osmel
  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
Sphingolipids are an extensive class of lipids with different functions in the cell, ranging from proliferation to cell death. Sphingolipids are modified in multiple cancers and are responsible for tumor proliferation, progression, and metastasis. Several inhibitors or activators of sphingolipid signaling, such as fenretinide, safingol, ABC294640, ceramide nanoliposomes (CNLs), SKI-II, α-galactosylceramide, fingolimod, and sonepcizumab, have been described. The objective of this review was to analyze the results from preclinical and clinical trials of these drugs for the treatment of cancer. Sphingolipid-targeting drugs have been tested alone or in combination with chemotherapy, exhibiting antitumor activity alone and in synergism with chemotherapy in vitro and in vivo. As a consequence of treatments, the most frequent mechanism of cell death is apoptosis, followed by autophagy. Aslthough all these drugs have produced good results in preclinical studies of multiple cancers, the outcomes of clinical trials have not been similar. The most effective drugs are fenretinide and α-galactosylceramide (α-GalCer). In contrast, minor adverse effects restricted to a few subjects and hepatic toxicity have been observed in clinical trials of ABC294640 and safingol, respectively. In the case of CNLs, SKI-II, fingolimod and sonepcizumab there are some limitations and absence of enough clinical studies to demonstrate a benefit. The effectiveness or lack of a major therapeutic effect of sphingolipid modulation by some drugs as a cancer therapy and other aspects related to their mechanism of action are discussed in this review.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SDCBP modulates stemness and chemoresistance in head and neck squamous cell carcinoma through src activation

  • Mir Pérez, Cristina|||0000-0003-3137-6521
  • Garcia Mayea, Yoelsis|||0000-0002-9395-7471
  • García Fernández, Laia|||0009-0008-3105-493X
  • Herrero, Pol|||0000-0002-8746-7214
  • Canela, Núria|||0000-0003-0261-2396
  • Tabernero, Rocío|||0000-0002-5949-0898
  • Lorente Guerrero, Juan|||0000-0002-3264-0251
  • Castellvi, Josep|||0000-0001-5745-9996
  • Allonca, Eva|||0000-0002-2532-5421
  • García-Pedrero, Juana
  • Rodrigo, Juan Pablo|||0000-0003-3063-0890
  • Carracedo, Ángel|||0000-0003-1085-8986
  • Lleonart, Matilde Esther|||0000-0002-6196-7405
To characterize the mechanisms that govern chemoresistance, we performed a comparative proteomic study analyzing head and neck squamous cell carcinoma (HNSCC) cells: CCL-138 (parental), CCL-138-R (cisplatin-resistant), and cancer stem cells (CSCs). Syntenin-1 (SDCBP) was upregulated in CCL-138-R cells and CSCs over parental cells. SDCBP depletion sensitized biopsy-derived and established HNSCC cell lines to cisplatin (CDDP) and reduced CSC markers, Src activation being the main SDCBP downstream target. In mice, SDCBP-depleted cells formed tumors with decreased mitosis, Ki-67 positivity, and metastasis over controls. Moreover, the fusocellular pattern of CCL-138-R cell-derived tumors reverted to a more epithelial morphology upon SDCBP silencing. Importantly, SDCBP expression was associated with Src activation, poor differentiated tumor grade, advanced tumor stage, and shorter survival rates in a series of 382 HNSCC patients. Our results reveal that SDCBP might be a promising therapeutic target for effectively eliminating CSCs and CDDP resistance.